Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Survival Without Persistent Limiting Toxicity: a Real Life Prospective Cohort of Advanced Neuroendocrine Tumor Followed in the French ENDOCAN-RENATEN and GTE Networks

NCT07471425 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT07471425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07471425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Survival Without Persistent Limiting Toxicity: a Real Life Prospective Cohort of Advanced Neuroendocrine Tumor Followed in the French ENDOCAN-RENATEN and GTE Networks
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Observational
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
June 30, 2034
Enrollment
1,100 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine (ne) tumors